Jazz Pharmaceuticals Director Bruce Cozadd Sells $1.3M in Shares Under 10b5-1 Plan

Executive Summary

On November 4, 2026, Jazz Pharmaceuticals plc director Bruce C. Cozadd reported the open-market sale of 6,000 ordinary shares conducted on November 2, 2026. The transaction executed at an average price of $215.84 per share, totaling approximately $1.30 million. Following the sale, Cozadd retains direct ownership of 339,875 shares.

Transaction Details

• Security: Ordinary Shares
• Transaction Type: Open-market sale (Transaction Code S)
• Shares Disposed: 6,000 shares
• Execution Price: $215.84
• Gross Proceeds: $1,295,040.00
• Post-Transaction Direct Holdings: 339,875 shares

Market and Trading Context

• Rule 10b5-1 Trading Plan: The transaction was pre-arranged pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025. Pre-scheduled transactions under Rule 10b5-1 occur automatically and carry lower signaling impact regarding insider sentiment.
• Portfolio Impact: The 6,000 shares sold represent roughly 1.73% of Cozadd's holdings prior to the trade, leaving him with significant skin in the game (339,875 shares valued at over $73 million at current transaction levels).
• Significance Assessment: Low. The trade is a planned disposition of a modest fraction of his equity position.